Smith & Nephew plc (SN) Earnings Call Transcript
August 4, 2026
Earnings Call Speaker Segments
Good morning, everyone, and welcome to the Smith & Nephew Q2 and half-one results presentation. I'm Deepak Nath, Chief Executive Officer, and I'm joined by John Rogers, our CFO. During this quarter, our underlying revenue growth came in at 1.6%, below what we had expected. Sports Medicine and ENT once again delivered strongly, with consistent performance across regions and categories, and many of our key products posted double-digit growth. That said, softness in US Orthopaedics and in Advanced Wound Bioactives offset this. In US Orthopaedics, knees are still weak, reflecting dynamics similar to Q1, though as expected we saw sequential improvement, and we do expect further improvement over the remainder of the year. US hips were affected by a delay in CATALYST stem deployment and a tough comparator, with growth expected to resume as deployment increases during the balance of the year. Within Bioactives, SANTYL growth was mainly impacted by strong distributor demand in the prior quarter, which did not repeat. This should normalize over the balance of the year. Despite the slower start on revenue, trading profit was strong at $566 million. Excluding M&A, trading profit grew by 9%, supported by efficiency savings that came in stronger than expected and by tariff refunds that fully offset the forecast tariff headwinds.
Turning to how revenue has performed, for 2026 we now anticipate underlying growth of roughly 4%. We know Orthopaedics isn't where we'd like it to be, yet our focus stays on improving results as we reinforce the portfolio and continue the margin gains we've achieved. Across all three business units we have distinct growth drivers backing our outlook for the rest of the year. Crucially, even with the updated revenue outlook, we still anticipate delivering our original guidance for profit, trading profit, free cash flow, and ROIC. That covers an extra 50 million of efficiency savings we identified for 2026, lifting our total expected savings to $200 million from $150 million, plus a broadly neutral tariff effect, net of refunds. The steps we took under our 12-point plan have left the group more resilient and better equipped to handle these challenges. With that, I'll pass things to John to walk you through the financial performance, and I'll return once he's finished. John?
Thanks, Deepak. Quarterly revenue came in at $1.6 billion, which works out to +1.6% underlying growth and 2.8% reported, and that reported figure includes a 120 basis point tailwind from foreign exchange. Looking at geography, the US was down 1.3%, a reflection of softer performance in Orthopaedics and Advanced Wound Bioactives. Other established markets posted 1.7% growth, led by Canada, Australia, and New Zealand, which carries on the good momentum we saw in the first quarter. Emerging markets rose 10.6%. On an underlying basis, group growth was 1.4% once you exclude China, and our expectation remains that China will be broadly neutral to growth for the full year. Now let me walk you through the business units in more detail. First up is Sports Medicine and ENT, which delivered another excellent quarter with 8.6% growth. Inside Sports Medicine, the underlying growth drivers are the same as before, reflecting continued momentum of our key growth platforms and consistent performance across the portfolio. Growth was broad-based across regions, and joint repair once again posted double-digit growth, backed by strong demand for Q-FIX Knotless and REGENETEN. In AET, FAST-FIX and services remain the main contributors to growth. In China, having intentionally restricted inventory in the channel at the end of last year and ahead of VBP implementation, we saw strong demand for our products during the quarter.
We still anticipate VBP going live in the second half. Revenue from Sports Medicine once more came in above our recon, and robotics revenue did too. Moving on to ENT now: beyond China, growth was robust worldwide — including double-digit gains across other established markets and emerging markets, plus our AERIS coblation wands for turbinate reduction and our HYLE wand for tonsil and adenoid procedures. In China, we keep drawing down channel inventory as we approach VBP implementation, and that weighed on our growth. Our expectation for the profit headwind from China VBP remains roughly 15 to 20 million for the full year. Now let's turn to Advanced Wound Management, which was down 2.1% in the quarter. Inside that, Advanced Wound Care rose 3.7%, with solid growth across the board, led by US ALLEVYN and momentum in our emerging markets. Our ALLEVYN Complete Care launch has gotten off to a strong start in the US, with encouraging early momentum, and we were glad to bring it to Europe this quarter. In Bioactives, revenue fell 12.7% for the quarter, reflecting the reimbursement change in skin substitutes and a soft quarter for SANTYL. SANTYL had benefited from strong distributor demand in Q1, which made Q2 softer.
We've also observed some effect from a payer that added prior authorization for particular doses of SANTYL. Demand at the base is still healthy, yet that change is generating friction in the prescription process, and we're acting to fix it, and we expect SANTYL to get back to growth in the second half. In our skin substitutes business, we keep confronting headwinds in the US stemming from CMS reimbursement changes that took effect at the beginning of the year. We saw sequential improvement versus the first quarter, led by hospitals. But volumes and pricing in non-surgical settings stayed under pressure, especially in Mobile, where our exposure is limited. The market is adjusting more slowly than anticipated, which keeps weighing on billing efficiency and inventory levels throughout the channel. We now expect the trading profit headwind from skin substitutes to land toward the upper end of the 20 to 40 million range we guided previously. We stay confident in the segment's long-term fundamentals and see opportunities to gain as the market normalizes. Advanced Wound Devices grew 3.8%. LEAF posted double-digit growth, reflecting robust demand. Both PICO and RENASYS did very well in emerging markets as we keep expanding geographically.
When it comes to PICO, sales across other established markets took a hit from doctors' strikes in Spain within the surgical sector, as well as from the timing of tender offers. In the US, RENASYS sales stayed soft in the acute care channel, though performance in the post-acute channel was good. Moving on to Orthopaedics, that segment fell 1% on an underlying basis, mainly reflecting the continuing problems in US knees ahead of new product launches and temporary headwinds in US hips. After four consecutive quarters of above-market growth in US hips, we saw softer performance this quarter against a tough comparator. CATALYST stem continues to grow strongly, but Q2 was impacted by delay in set deployments and an increasing proportion of existing customer retentions versus competitive conversions. We see a clear path to reacceleration over the remainder of the year as CATALYST stem set deployment increases. As the product moves into its third year post-launch, growth should remain strong, albeit at a lower rate than during the initial launch phase. US knees remain weak, but we are seeing gradual improvement as expected. The underlying dynamics are unchanged. Deliberate portfolio and capital discipline, combined with an ongoing market shift towards cementless, continue to influence performance in the near term.
The sequential gain came from solid demand for LEGION MS along with double-digit expansion in LEGION CONCELOC, our cementless product line. LEGION MS accounts for nearly 20% of our LEGION mix at this point, compared with 15% in Q1, and it's making our installed base more competitive. We still anticipate steady improvement across the year, powered by additional LEGION MS set deployments. That will stay the primary catalyst until LANDMARC comes to market. Beyond the US, knee results took a hit because a sizable tender order in the Middle East during the year-ago quarter wasn't repeated. Hips got a lift from the CATALYST stem launch in Japan, though we did experience some scattered softness in Australia, where we're waiting on regulatory clearance for CATALYST stem. Trauma & Extremities turned in a solid performance overall. Growth in EVOS, IM nails, and shoulder remains healthy, fueled by our AETOS implant. Competitor launches in the US are having an effect, but we look for growth to pick up in the second half as EVOS Pelvic is introduced and TRIGEN MAX ramps. Lastly, other recon was up 0.8%. This business tends to show some quarter-to-quarter variability, since revenue depends on contract timing and mix. That was more evident this period, given yet another tough prior year comparison.
Having said that, we recorded double-digit expansion in CORI installations worldwide, together with ongoing gains in utilization and penetration. We anticipate that growth will pick up during the second half, helped by an easier comparator in Q3, sustained robust demand for our robotics platform, and solid adoption among ASCs and teaching institutions. I'll now turn to the half year financials. Revenue for the half year came in at $3.1 billion, rising 2.3% on an underlying basis and 4.6% on a reported basis. We had one fewer trading day compared with the prior year, and underlying revenue growth was 3.1% measured on an average daily sales basis. In line with what we saw in Q2, Sports Medicine delivered strength, which was offset by softness in US Orthopaedics and Advanced Wound Bioactives. Turning to the summary P&L, underlying gross profit reached $2.2 billion, a gross margin of 71.1%, up 60 bps year on year. The driver was efficiency savings across manufacturing and procurement that came in above expectations, more than offsetting cost inflation and the headwind from inventory revaluation. Tariff refunds completely offset the tariff headwind we had forecast for gross margin. Trading profit rose 43 million to $566 million, and trading margin expanded 60 bps to 18.3%, reflecting the gains from a higher gross margin and continued cost savings.
Continuing down the income statement, IFRS operating profit was up 4.3%, which mirrors restructuring charges that are temporarily higher, stemming from additional optimization work across our manufacturing network, along with increased acquisition costs arising from, naturally, the Integrity deal. Basic earnings per share rose faster than that, at 6.2%, which mirrors the buyback we announced at Q1, while adjusted earnings per share climbed 11% to 47.7 cents. At 15.6 cents per share, the interim dividend represents a 4% increase over half one 2025. Let me now walk you through a more detailed bridge of how our trading profit grew. We absorbed 119 million in headwinds stemming from cost inflation, inventory revaluation, changes to wound reimbursement, and China VBP, even as we kept investing 33 million in our growth. Those headwinds were more than offset by 59 million of operating leverage and 128 million of efficiency savings, which I'll cover in greater detail shortly. Although we had previously guided to an incremental tariff headwind in 2026, refunds received during the first half meant net tariffs ended up broadly neutral to profit growth. Foreign exchange likewise had a broadly neutral impact. Taking all of this together, trading profit growth came in at 9%, excluding 4 million of dilution from the acquisition of Integrity Orthopaedics. As I mentioned, turning now to efficiency savings, we've delivered roughly 133 million in the first half, well ahead of expectations.
Roughly 50 million of that total was delivered by the 12-point plan and zero-based budgeting efforts, which means cumulative savings have now reached 330 million since we began these programs. That puts us at the bottom of the 325 to 375 million range we set out at our 2024 interim results — over a year early. We anticipate additional benefits coming through for the rest of '26 and on into 2027. The other 80 million during the first half was generated by further opportunities in procurement, manufacturing, sales and marketing, and business support functions. We're looking for another 70 million of savings in the second half, drawn from the 12-point plan and ZBB as well as other opportunities. That lifts our forecast efficiency savings for the year to roughly 200 million, up from about 150 million previously. The extra 50 million should come mainly from manufacturing — including continued footprint optimization — plus procurement and sales and marketing. Trading profit guidance for 2026 stays as it was. We expect to deliver reported trading profit growth of around 8% excluding M&A and trading profit of around $1.3 billion including the Integrity impact. Our current expectation is that tariffs will have a broadly neutral year-on-year effect on trading profit, net of refunds.
The skin substitutes drag should land near the top of the 20 to 40 million range we guided to earlier, and nothing has changed in our assumptions on inventory revaluation or China VBP. As we've said before, the Integrity Orthopaedics deal should be slightly dilutive to trading profit in 2026, roughly neutral in 2027, and accretive starting in 2028. Turning to trading margin by business unit, Sports Medicine and ENT rose 160 bip to 24.7%, Wound fell 10 bip to 22%, and Orthopaedics gained 30 bip to 13%. Within Sports Medicine and ENT, operating leverage and efficiency savings fueled the expansion. At Wound, the modest decline came from US skin substitute reimbursement changes, mostly offset by savings initiatives. For Orthopaedics, manufacturing savings from network optimization, ongoing productivity initiatives, and disciplined cost control more than offset the inventory revaluation headwind and softer revenue growth. We anticipate additional margin expansion over time as we work through the inventory revaluation headwind and gain from improving revenue growth, the impact of actions already taken to rightsize our manufacturing capacity, and our Ortho 360 operating model.
These results show the operational excellence we're driving throughout the business. Inventory is still a key focus for us, even now that the 12-point plan has been completed. Group DSI — days sales inventory — dropped by 72 days, including the reclassification of instrument sets from inventory to PPE, and by 40 if you strip that out. The larger decrease came in Orthopaedics, down 62 days excluding reclassification, which reflects ongoing efforts to cut the number of units held in inventory and an emphasis on capital efficiency. We also saw Sports Med DSI come down, though to a smaller degree than Orthopaedics, and Wound DSI was unchanged, excluding the reclassification. Sports and Wound are both already considerably nearer to industry benchmark DSIs. We expect further inventory progress in 2026. Now, turning to cash flow, trading cash flow came in at $437 million for the first half, roughly 50 million lower year on year, but that reflects a $51 million step-up in CapEx versus a year ago, driven by investments in our new wound manufacturing facility in Melbourn and in some IT investments. We don't expect that increase to repeat in the second half, and cash generation should improve compared with half two 2025.
Other working capital came in higher, mainly because of when bonus accruals and the related cash payments landed. Cash conversion stood at 77%, and we expect that figure to get better as the year goes on. Free cash flow reached $231 million, a decrease of 13 million compared with a year earlier, which again mirrors the factors I just described and was partly offset by lower restructuring cash costs. Our expectation for free cash flow in 2026 remains roughly 800 million, powered by profit growth and our ongoing attention to working capital, offset by a modest short-term rise in restructuring costs. Over the first half, net debt rose to 3 billion, up 260 million, which puts our leverage ratio at 1.8 times adjusted EBITDA — inside the target we set of around two times. That increase came from investing in our business, buying Integrity Orthopaedics, a growing dividend and, naturally, the 500 million buyback we announced in Q1, of which we have in fact now finished 260 million as of the 3rd of August. All of this aligns with how we prioritize capital allocation. Before I get to guidance, I'd like to point out the headway we keep making on margins, working capital, cash flow and returns.
According to the speaker, this improvement across the board shows that operational controls are stronger and helps make Smith & Nephew a more resilient business, better positioned to manage through periods when revenue is soft or external challenges arise while keeping progress against our long-term objectives. Turning now to our updated outlook, reflecting softer performance in US Orthopaedics and SANTYL, we now expect second half growth to be in the range of 5 to 5.5% and full year growth to be around 4%. Notwithstanding the lower revenue outlook, all other metrics of our guidance are being maintained. We continue to expect around 8% trading profit growth excluding M&A for the year, and this translates into approximately $1.3 billion of trading profit, including marginal dilution from the Integrity acquisition. This reflects the step-up in efficiency savings that we are delivering across the business, together with the removal of the forecast tariff headwind. The progress we demonstrated in the first half gives us confidence we can remain disciplined on costs while supporting improved revenue growth in the second half. We also remain on track to deliver around 800 million of free cash flow and a return on invested capital above 10%. Let me finish by outlining why we are confident in a step-up in revenue growth.
For the second half, we're looking at growth of 5 to 5.5%, and that comes from drivers in each of our three business units. Within Sports Medicine, we anticipate ongoing momentum across the segments, with notably strong growth in REGENETEN and FAST-FIX. For Advanced Wound Management, we anticipate stabilization in US skin substitutes, which builds on the sequential improvement from Q1 to Q2. We also anticipate SANTYL getting back to growth, more rollouts of ALLEVYN Complete Care across Europe, the continuing launch of next-generation LEAF, and the payoff from heavier investment behind PICO. In Orthopaedics, we anticipate an improving trajectory for US knee implants, powered by LEGION MS and the cementless version of LANDMARC now launching. We likewise anticipate US hip implants getting back to growth as more CATALYST stem sets are deployed. Naturally, the fourth quarter also gives us one extra trading day. With that said, I'll turn things back to Deepak.
Thanks, John. Before we wrap up, I’d like to take a few minutes on the progress achieved in the first half against each element of RISE, which serves as our plan for the coming 3 years. These steps are intended to reinforce the company now and get us ready for durable expansion over the longer horizon. To serve more patients, we keep widening access to our technologies by moving into new geographies, bringing out fresh products, and hitting meaningful clinical checkpoints throughout the portfolio. That includes doing the first knee and shoulder cases with our CORI XT handheld robotics platform, along with launching ALLEVYN Complete Care and RENASYS EDGE in Europe. On the innovation side, we moved the pipeline forward, built up our clinical proof, and introduced several new offerings across all business units, such as FLOW EXTEND and LYNX in Sports Medicine and ENT, EVOS Pelvic in Orthopaedics, and LEAF 3.0 in Advanced Wound Management. With those, the count of products launched so far in 2024 reaches nine, which keeps us firmly on pace to deliver 16 for the entire year. One major moment was getting FDA clearance for THESIS, our spatial surgery system, which I’ll discuss in just a bit.
When it comes to scaling, we keep putting money behind the growth opportunities we've prioritized most highly. That includes buying Integrity Orthopaedics, which makes our leading shoulder repair portfolio stronger, expanding the sales force for PICO, and continuing to make headway at our new advanced manufacturing facility in Melbourn, which is still on schedule to open in 2027. On execution, our focus stays on boosting productivity throughout the group, simplifying the portfolio, and operational excellence, and we're progressing well when it comes to streamlining that portfolio, which will let us handle considerably fewer SKUs across our value chain and lift our capital efficiency. Earlier this quarter, the Shingo Prize — a prestigious honor — went to our Advanced Wound Management manufacturing facility in Suzhou, China, which speaks to more than a decade of sustained operational excellence and continuous improvement. Importantly, these are not merely strategic priorities; they are turning into tangible growth platforms that we think can generate value for shareholders for many years ahead. Innovation offers the clearest illustration of this, since we're assembling a portfolio of technologies designed both to capture share in markets that already exist and to create wholly new growth opportunities. In Sports Medicine, we now hold four differentiated growth platforms, which we call our Big 4. REGENETEN keeps performing strongly, posting roughly 20% growth in the first half, and there's substantial runway left to grow penetration in rotator cuff repair as well as across other tendons and extra-articular ligaments.
The acquisition of Integrity is doing better than we had anticipated, and integration is moving along nicely as we boost production capacity and broaden our commercial reach. With CartiHeal's Agili-C, we're continuing to raise awareness and drive adoption in the US ahead of new reimbursement starting in January 2027, and we're also growing internationally, with our first cases finished in Australia, Italy, and Belgium. This quarter brought a key milestone: FDA approval of THESIS, the industry's first spatial surgery platform. THESIS brings together advanced imaging, navigation, and AI-enabled assistance so surgeons can carry out arthroscopic procedures more precisely. Its first application is femoral tunnel drilling, though we believe there's a substantial long-term chance to take the platform into multiple joints and procedures. In Advanced Wound Management, ALLEVYN Complete Care reinforces our standing in one of the biggest and quickest-growing parts of the wound care market. Early feedback from customers has been positive, pointing to real differentiation against products currently available on the market today. We're also broadening our wound market with the recent launch of LEAF 3.0 and by taking PICO into new care settings and patient populations. In Orthopaedics, we keep building a connected ecosystem around CORI, tying together planning, execution, and outcomes to enable more personalized care and better optimized clinical workflows.
CORI XT serves as the basis for the robotics platform we already have. Our first robotic shoulder procedures using XT took place in February, the first knee procedures on it happened in May, and hip execution is still on schedule for launch during the first half of 2027. Beyond robotics, implant innovation keeps building momentum. CATALYST stem is expanding and turning into a significant contributor in hips, and in knees, more set deployments are helping drive wider adoption of LEGION MS. We also anticipate the third-quarter launch of LANDMARC, the most robotically enabled implant system we have created so far. Taken together, the breadth and strength of these innovation platforms leave us confident in our capacity to produce sustainable growth over time via market expansion, share gains, and new category creation. To sum up, second-quarter performance came in below what we expected, as strong momentum in Sports Medicine was offset by softness in US Orthopaedics and Advanced Wound Bioactives. As a result, we are lowering our revenue outlook for the year. Even so, we remain confident that growth will step up in the second half, and John has walked you through the drivers behind all of that across our business units.
It's important to note that although we're reducing our revenue outlook, we're still on course to hit our original guidance for trading profit, free cash flow, and ROIC. That's backed by an upgraded forecast for efficiency savings — among them an additional 50 million in savings we've now identified — which helps counterbalance the effect of slower revenue growth. We're also continuing to make the business more resilient and agile. We're putting investment behind our growth platforms while pushing through gains in margin, cash flow, and returns, which strengthens our capacity to respond effectively to challenges. Orthopaedics isn't where we want it to be, but we're staying focused on better execution and improved performance. At the same time, we're positioning the business to take advantage of the significant opportunities we see ahead. These include the LANDMARC launch in knees, robotic execution on CORI in hips, the Big 4 in Sports Medicine, launching new products and entering new settings in Wound, and our wider pipeline of innovation. All of this together reinforces our confidence in the underlying strength of the business and in our ability to create long-term value. With that, we're ready for your questions.
Hello. Jack Reynolds-Clark here from Morgan Stanley. Thanks so much for taking my questions. I've got three, please. First, regarding US Orthopaedics, could you walk through exactly what went wrong there, how much of that was the market versus other kinds of issues, and what you're seeing so far in Q3 — and does it affect your assumptions about mid-term margin expansion? Then on 2026, the H2 guide clearly implies a fairly substantial step-up compared with H1. Given the comments about the VBP delay, where do you expect the biggest half-on-half step-up on a segmental basis, and really what gives you confidence in that new guide? Lastly, on the mid-term guidance, 4% growth in 2026 is very much below the mid-term guidance range. What do you see stepping up in future years to offset that?
Okay, I'll address that next. In US Ortho, there is a degree of market deceleration, yet that isn't the primary driver. What really drives it are factors specific to the company. At the core, it comes down to knees. We had already signaled that we trail the market, mostly owing to the gap in our portfolio — we cannot take part in the fastest-expanding segment of knees, namely cementless. That offering covers just one-half of our installed base, and once we launch LANDMARC in Q3, we'll be in a stronger position to keep the market in the remaining half, where no cementless option exists. That is far and away the largest driver. It's the difficult issue we are working through. We identified it as a factor back in Q1, we still saw it during Q2, though there was a bit of sequential improvement. I'll get to what we anticipate for half-on-half shortly, but that is the core factor behind the softness in US Ortho. There was a short-lived dip in US hips. CATALYST stem kept growing at a very healthy pace, but we are now in the third full year since launch. We do expect that, as we move forward from this point, at some stage we will need to shift from competitive takeouts toward retaining more of our business, holding on to it.
That is going to take place as we move through the launch. Deployment of sets was slower than we had expected. Instrument sets get optimized for one product or the other. For instance, when you are attempting to win business from one competitor rather than the other competitor, we need instrument sets that differ slightly. Getting that right is somewhat difficult. That is what held back our set deployment during the quarter. It is a blip. We expect to make that up in the back half of the year. Those are really the fundamental factors, rather than a slowdown in procedures, though there was some of that. On a half-on-half basis, what we fundamentally expect in Orthopaedics is LEGION MS, which strengthens our LEGION offering, correct? That is going to be the most material driver. Then as we bring LANDMARC porous onto market, which will largely be a Q4 effect, as I said, we will be able to better retain the business that we have. Then once we get into 2027, when we have the complete offering with LEGION cemented as well by the end of Q2, we will be able to go from defense into more of an offensive crouch. In Orthopaedics, it is LEGION MS and the launch of porous. In Sports, we will continue the trend that you have seen quarter-on-quarter.
Honestly, if you strip out the China impact, Sports hasn't shown much of an H1 versus H2 pattern, and our expectation is that this will hold true again this year. On the Wound side, that's PICO. We're putting investment behind expanding PICO geographically. Some early evidence of that is showing up in Q2, though we anticipate it will gather momentum during the back half of the year. Next, skin subs, where we saw sequential gains from Q1 into Q2. As we've noted, we're sitting at the upper end of the guidance range we provided regarding the reimbursement impact, but from H1 to H2, we anticipate improvement. Those are the pieces behind the H1-to-H2 story in terms of what drives the acceleration in growth we're seeing. Finally, moving to the third question about mid-term guidance — look, we always understood '26 would be a tough year. Clearly, it's turned out somewhat tougher than we anticipated, and that's mostly driven by the US knees situation we discussed and the prior authorizations that one of the bigger insurers introduced this year, which is creating more friction in the system — with prescriptions, not end-user demand, but really the pace at which prescriptions are being filled.
So that is why we moved the call to 2026. The core growth engines — new products, whether inside existing categories or forming brand-new ones — are still very much in place. In Orthopaedics, for instance, we mentioned the LANDMARC launch, hip execution on CORI, AETOS for shoulder, and in trauma we're completing our EVOS lineup with the new pelvic offering, while on the nail side of the portfolio, IM nails keep showing their strength. So Orthopaedics has plenty of growth engines to look forward to in 2027. Then in Sports, it's continued execution on the Big 4. And lastly, in Wound, there's PICO, the build-out of RENASYS, and normalization in skin subs. As you can see, these growth engines are numerous across every one of our business units. That gives us confidence we are fundamentally a company growing at 6 to 7%.
Yeah.
Appreciate that. Perhaps a bit of detail on how the phasing plays out across the second half, Q3 and Q4. We anticipate Q4 showing a step-up in performance compared with Q3. Q3, clearly, will be better than Q2, and Q4 then comes in stronger still. This isn't a promise about tomorrow. It's very clearly down to the timing of the investments we are making, particularly around the LANDMARC launch. Then, when it comes to skin substitutes, we're actually beginning to lap last year's impact. Our Q4 last year was difficult in skin substitutes owing to the actions the market was taking in anticipation of reimbursement changes. We have a much softer comp in Q4 on skin subs, and not only is there the continued recovery we've already seen from Q1 to Q2, which we'll see come through in Q3, but we also start in Q4 to lap last year's impact, so that will be particularly positive on skin subs. Then, of course, dare I say it, we should mention as well that we have one extra trading day in Q4, and when you add all of that up, you'll see a big step-up in growth in Q4 versus Q3, just to make that absolutely clear.
Now, regarding what you mentioned about the challenges in Sports — you're correct. Deepak is completely right, naturally, that the momentum is still there, but Q3 should be somewhat weaker for Sports and ENT compared with Q1 and Q2, since VBP will hit both of those areas during the second half. That has been included in our forecast, and it is entirely reflected in the top-line guidance expectation of 4% as well as in the profit guidance, which stays the same.
That's great, thanks. Mind if I squeeze in a quick follow-up? If you had to put numbers on the growth for Q3 versus Q4 — the phasing between them — could you give us any color on that?
Yes, I can.
So,
My view is that Q3 growth will be along the lines of what we saw in Q1 — similar dimensions. As you'll recall, Q1 gave us 3.1% growth, or 4.7% on an ADS basis. Q3 should deliver growth at a comparable level. Then in Q4, that growth steps up. You can do the maths yourself, but the growth level will be around 6 to 7%, though on an ADS basis it'll actually be just north of 5%, given the additional trading day. Measured in absolute terms, that's a step-up from Q3 — we're not stripping out the trading day effect there — and it comes about because of the skin subs, because of the investments we're making in PICO and the timing of those investments, and of course because LANDMARC launches toward the end of Q3. Those factors are why we feel confident about our ability to deliver that 4% for the full year.
That's great. Thanks a lot.
Good afternoon. Hassan Al-Wakeel here from Barclays. I have a couple of questions about Ortho. First, to frame Jack's question in a somewhat different way: we saw softness this year, and now hips, which had been really strong before today, are showing it too. You've indicated this isn't driven by the market. What are you changing on the execution side? Why shouldn't some of these set delays in hips put pressure on the second half? And specifically on US hips, how are you viewing growth there past the next quarter or two, as CATALYST stem matures as a product? Second, on robotics, if you could try to break down the growth in the quarter and what's happening with CORI, is it purely a function of comps, and how should we think about growth in the second half and beyond, given that Mako OPS launched last month?
All right. Regarding hips, I want to stress once more what I mentioned about set deployment — at the outset, there was a comparator, correct? A tough competitor showed up in Q2, and that, in numerical terms, made a difference. If you examine the two-year stack, hips really aren't slowing down by much; by and large it holds fairly steady. On set deployment, to expand on what I noted, it mostly comes down to instrument sets. Whenever you attempt to move a customer off their current method — be it a legacy product of ours or something from a competitor — the instrument you must place to match that specific surgeon's surgical approach carries some variability. It isn't simply a standard instrument you put in place that functions no matter which legacy platform they happen to use. Nailing the demand for that instrument is somewhat difficult given that variability, correct? We didn't manage that perfectly, and as a result we were somewhat constrained by it in Q2, correct? The mix of a numerically tougher comp plus that is basically what produced the outcome you observed. We've also noted that as the launch moves forward, what usually occurs with Orthopaedics launches — at least in the way we handle CATALYST stem — is that we went after competitive surgeons first, correct?
You’d expect to keep doing that for some window of time, but at some point you’re going to have to turn to your customer base. That blend of competitive versus retention is going to begin flipping—away from competitive-heavy against retention and toward more retention-heavy, with a smaller competitor. Eventually that will settle down, and we’ll return, in effect, to market levels of growth in hips. That’s what you should anticipate as we move into the back half of this year and beyond. Hopefully that clarifies what was sort of a blip in the sort of instrument deployment that paced Q2, but here’s what you should expect as we go through the launches. Your second question was about CORI, for this quarter and beyond. I think, John, you said you had double-digit growth in CORI placements in quarter two and also that you got a similar number in the first half. We remain pleased with the pace at which we’re placing CORI and also with where we’re placing them, right—hospitals versus ASCs, teaching institutions versus across the mix. We’re actually seeing a nice impact across a range of care settings. Broadly speaking, when I look across the board, we are at least at our market share, which is encouraging.
Looking at the ASC, CORI placements there are a bit ahead of where our market share sits—not dramatically so, but definitely ahead. What that tells us is we're tracking in line with our share. Our approach isn't to drop a unit in first and hope utilization follows later. We put systems where demand exists, where there's a surgeon eager to bring it into their practice, and we watch utilization just as closely as we watch placement—right? We might have gone a different route, but placement plus utilization is what we've chosen. I'm happy not just with the headline figure but with the texture of it as well. You brought up Stryker and their handheld. For me, the headline always raises the question: is CORI some kind of science experiment? Is it truly a mainstream platform or not? The most recent number we reported, the one we discussed, was 1,100. We've spoken about double-digit growth on top of that, so you can do the rough math. The fact that we're placing in proportion to our shares shows CORI is a mainstream product. The market is accepting it. The fact that competitors now feel they need their own handheld platform validates our approach and also speaks to the innovation present at Smith & Nephew at our scale, where we've made bold bets.
We might have chosen a fixed-arm robot instead of our handhelds as well, but that's not what we did, correct? We possessed enough confidence in our judgment to commit to a handheld platform, and it's wonderful that rivals are now doing the same. Ultimately, what matters is putting them to work through the playbook we've built, and I have a lot of confidence in the way we're carrying that out. Those, I believe, are the questions you raised.
To add a bit to what Deepak said, and even with placements growing at a double-digit rate — and of course, when CORIs are first placed, they begin at low utilization and then ramp up gradually over time. Even with that double-digit growth in placements, we keep seeing progress on both utilization, which is up four or five percentage points since the end of 2025, and penetration, which is up roughly two percentage points since the end of 2025. Even with the dilutive effect of putting out more CORIs and the build-up curve those require, we are still seeing improving trends in penetration and utilization, which I think is very encouraging.
Okay. I don't show any leftward bias in whom I pick, so I'll head to the right side of the room and take questions from colleagues over there, and after that I'll move around the room. Thank you.
Seb Jantet from Panmure Liberum here. I have just a couple of questions, then. On tariffs, the guidance has clearly changed, but I recall you mentioning a $60 million impact before that. I just want to confirm that the gross and net figures remain the same, so the refund is still $60 million, and to check the logic that this simply moves as a headwind into '27 rather than '26,
Right. Fair enough. So everyone is completely clear on tariffs: the impact on the P&L last year came to 15 million. For this year, the anticipated P&L impact stood at 60 million, which represented a 45 million drag. Our expectation now is that refunds this year will land at roughly 50 million. When you net it all together, the broad takeaway is that tariffs overall, measured against last year, come out neutral on the P&L. What would otherwise have been a P&L charge gets effectively offset by those refunds.
So next year, will we essentially be facing that headwind, then?
You'll see that headwind in the coming year. The cash tariffs come to roughly 50 million, and the P&L hit next year should be around that same amount. A few additional refunds are also likely to flow through next year. Look, tariffs involve plenty of moving pieces, and the outcome of the Section 232 review remains to be seen — we probably won't learn it until the back end of this year. As you'd always expect, there are lots of moving parts where tariffs are concerned, but we would anticipate that some further refunds will partly offset the P&L charge next year. Obviously, we'll give more guidance on that when we get to our prelims in 20.
Thank you. Moving to the second question, it concerns cost savings, and clearly you've built some decent momentum there. If I understood you right, you said the additional 50 million comes mostly from manufacturing and areas such as footprint reduction, that sort of thing. I'm just curious — in my experience those take a fair amount of time to deliver, so how did you manage to uncover new ones so quickly?
We're seeing substantial efficiency gains from how our facilities are operated. Some of the benefit flowing through stems from past changes that performed better than anticipated. Part of it is historical adjustments that have come through stronger than expected in terms of how they've moved through the P&L. On top of that, there are changes we've implemented in how we run things. We've further streamlined operations — for instance, from Austin as well as Warwick, which we closed. That was consolidated into our Memphis facility, and the efficiency savings delivered there have exceeded expectations. These efficiency savings aren't confined to manufacturing. Most of them, as you correctly point out, sit in manufacturing, but we're also seeing savings in sales and marketing. In addition, there are savings showing up in our business services too.
Procurement.
On procurement — yes, thanks, Deepak. Yeah, I think this is really exciting. When I look back at what we said with Q1, or the preliminary figure, I believe I noted at that point 150 million, maybe a bit more. We'd always had some visibility that let us see a path past that 150 million. So being able to discuss a 200 million target today feels very good. It genuinely shows a discipline that keeps going on cost savings — one we first established through the 12-point plan and later extended with the ZBB program. Right now we're examining the next wave, and we won't go into too much detail on it, but much of what we're doing — for instance, installing new systems plus layering in AI — and there's a great deal of work underway in the business today examining how we can fundamentally simplify and streamline our end-to-end processes, which stay fairly complex. We've been through roughly three phases of cost reduction in our business. The first one was simply getting the P&L into decent shape so we could deliver the numbers.
The second one basically involves taking our current processes and removing some of what we refer to as the fat and the cost within them. The third wave consists of fundamentally simplifying, automating, and streamlining our processes, and we are now in that third wave. Without a doubt, we'll discuss more in the future about what the upcoming opportunity is. Perhaps
Two points, really. First, a bit of clarification — or more of a broader observation. When we discuss footprint, it isn't the case that we're shutting additional plants beyond those we had already planned; and you're correct that those initiatives take time. What really matters is the way we're leveraging the footprint we already have. Apart from everything John mentioned, that is the main factor — how we deploy Malaysia against Memphis, for instance, to optimize across the network in Orthopaedics. That contributes to it. We've highlighted the spirit of continuous improvements as the core underlying element that makes this strategy work. I'm glad to say several of those elements have been embraced by the organizations very, very well. That spirit of continuous improvements, which generates these extra savings, isn't a one-time event — it's genuinely the way we run the business, and that is what has let us maintain a profit target even with the revenue miss. Yes, the tariff headwind we anticipated didn't materialize, but there's more to it than that, correct? All of these extra savings are what make essentially that simple statement come true.
Thanks. This is Charles Weston at RBC. I just want a quick clarification on that: of the 50, how much is essentially pulled forward from 2027, and how much is incremental? And what should we be modeling off that for 2027?
Sure. Would you like to handle that one, or should I? I think—
The way I look at it, some of that 50 relates to first half performance—there's a bit of pulling part of half two into half one. And regarding the back half of the year, part of it involves bringing some of half one '27 into half two of '26; it's a constant moving forward of things. What I'd say is, we're not going to sit here today and guide to '27 numbers, but my point is this isn't a one-time exercise. To use Deepak's phrasing from a moment ago—he deliberately chose the words continuous improvement—and I also mentioned some of the savings we're now driving through items such as our ERP program and AI as well. I'd say we have good visibility, and we won't be laying out the guidance right now, but we do have good visibility on future opportunities for driving additional efficiency savings in this business. We'll lay that out far more clearly, of course, when we provide guidance for '27. I would not characterize this as robbing Peter to pay Paul by pulling it forward from '27 into '26.
You can expect a great deal more of that in 2027.
Thanks. Sorry for the lengthy clarification — I actually had a couple of real questions. One is about ACA: have you seen any shifts in either procedure volumes or CapEx demand coming from US hospitals? Second, on the LANDMARC launch timing, could you confirm everything remains on track for both the cemented and cementless versions, and also the usual — I believe you mentioned a two-quarter ramp before those start generating meaningful sales? Thanks.
Yes, certainly. Regarding ACA, we did observe a certain effect on procedures. It shows up in elective procedures — some hospital systems have made comments about this, and we saw it too — though the impact wasn’t among the strongest, and we didn’t place excessive emphasis on it. There is a slowdown tied to ACA in procedures that we have observed, affecting both knees and hips. As I mentioned, that is not the main factor behind our performance. On LANDMARC timing, the porous version lands right at the close of Q3, so mostly a Q4 impact, while the cemented LANDMARC comes at the end of Q2 of 2027. As you point out, Charles, there is a ramp-up that goes with it. You mentioned two quarters. It’s not quite that simple. It hinges on competitive dynamics, correct? There are good and not-so-good approaches to bringing these launches to market, right? For one, you can commit a great deal of capital and drive a lot of trial at considerable capital expense, right? A more disciplined and appropriate approach for an Orthopaedics launch involves being far more careful about how you allocate capital to drive trial and, in the end, adoption.
Something we've improved dramatically as a company is capital discipline and capital efficiency in the Orthopaedics business, which we didn't have consistently. That does have an effect on the top line, correct, and we've pointed that out in earlier quarters. Our plan is to apply that same mindset of capital discipline and efficiency to the LANDMARC launch. What follows from that is a somewhat slower ramp, but I think it will be a more durable one, and it's also the more disciplined approach to these.
Thanks.
Of course. Richard, go ahead with one question, and after that we'll open it up to the line.
Thank you very much. This is Richard Felton at Goldman Sachs. For my first question, I'd like to touch on a topic that has surfaced with somewhat greater frequency in our discussions with investors, namely the possible competitive threat to SANTYL. Could you take us back through how large that product is at present, how the revenue is divided across the various care settings, and what you see as SANTYL's main competitive advantages? My second question concerns Advanced Wound Devices. I believe that across roughly the past 4 quarters, we have observed some slowing in that portion of the business, moving from growth in the double digits toward growth in the mid-single digits. What has been behind that, and how should we properly think about the path ahead for Advanced Wound Devices?
Sure. For SANTYL, product-level specifics aren't something we normally share. It's a product worth several hundred million dollars, correct? As you mentioned, in that category a big share of the market is effectively involved, and there is a certain amount of competitive activity there. I just want to stress that this isn't what's behind our numbers at present — I want to make that point clearly. What sets SANTYL apart is that no refrigeration is needed, so the supply chain is simpler. There's no pain tied to using our product, which is a feature some of our competitors have, right? One drawback is that the process is slower — the product takes time before it takes effect, right? That's among the downsides of SANTYL. That said, it has a proven track record when it comes to utilization across a range of use cases and across settings, whether that's an acute setting or when patients are discharged home with a prescription for SANTYL, right? It holds across all of those areas. We feel very good about how we're positioned within that category. We obviously have a line of sight into what competitor products are, what they offer, and how SANTYL continues to be differentiated relative to it. Of course, we're not resting on our laurels there.
We’ve got a next-generation product, and with it we’re looking to make SANTYL better than it is today—leveraging what already works well, such as the supply chain strengths and the fact that using the product involves essentially no pain—while actually making it work faster. That’s what our next-gen SANTYL is about. When it comes to AWD, there are two broad categories: single-use and traditional negative pressure. We also classify LEAF within that, and LEAF includes both the device component and the dressing component—just to disaggregate what sits inside our AWD, right? The deceleration you’re seeing is largely in our traditional negative pressure category, which is our RENASYS platform. There, as we’ve pointed out, we’re performing well in the post-acute segment, but we are not gaining share in the acute channel. The response to that is to actually have a better-rounded offering with RENASYS, right—both in terms of the next-gen canister and by actually having a whole assortment of dressings that are fit for purpose for the application, whether it’s OB-GYN, whether it’s GI procedures, orthopaedic procedures, and the like, with each one having a specialized kind of dressing—and we have a narrower range there than the large competitor in that space.
Clearly, we have work to do on the product development side, and building that out will begin in 2027. Most of the slowdown sits in the acute care portion of traditional negative pressure. With PICO on the single-use side, that product has served as a growth driver for us for a good while now, and beyond using it across care settings, we've actually put investment behind pushing it into geographies where our presence isn't the same today — that's part of the investment we've discussed — and we expect the payoff to show up in Q3 and particularly in Q4, correct? We keep performing well there. There is competitor activity in the single-use segment. We believe we're well-positioned in that space, but we also have our pipeline there that we expect — I think we highlighted this during our capital market day presentation — somewhere around the '28 time frame, we expect to bring out our next generation PICO. Hopefully that gives you a sense of how that segment is categorized and the dynamics inside it.
Sure,
Right. We'll take the online questions first, and after that I'll return to the room.
Thanks. Just a quick reminder—if you'd like to ask something over the phone lines, hit star and then 1 on your keypad at this point. Should you reconsider, press star and then 2. Before you get ready to pose your question, kindly make sure your device isn't muted on your end. We have our first question coming from Veronika Dubajova at Citi. Your line is open now. Please proceed.
Hi, guys. Good afternoon, and thanks for taking my questions. I have two, please. One is sort of slightly diving into the nitty-gritty, but I'm just curious to get your thoughts on what's happening in Trauma and Extremities. Obviously, we had a number of years post-AETOS launch where growth there has really accelerated pretty dramatically here today. Just curious, Deepak, if you can touch upon the dynamics you're seeing in trauma versus extremities, and is there anything you can do to get that trajectory back into the mid- to high-single digits? Then my second question is a big picture one, and I apologize, but I have to come back to the mid-term guide. I think even just to hit the low end of the 6 to 7% that you've guided to previously, if you are doing 4% this year, you have to be seven in the other two years, and that would be a pretty dramatic acceleration versus the trend we've seen in the last couple of years. I appreciate there are headwinds to this year, but there are also headwinds to last year and the year before. I'm just trying to understand the logic for why you are sticking to that 6 to 7%.
Do you see any path whatsoever that lands you somewhere other than the bottom of that range? What underpins your confidence right now to stick with it? Thanks, everyone.
Okay, thank you, Veronika. I’ll go through them in the order given. For Trauma and Extremities, I’ll discuss trauma first and then extremities. On the trauma side, we’re in a fairly good position thanks to our EVOS platform. I’ve mentioned pelvic, which represents roughly 1.5% of the total pie, but it’s a key piece we’re going to launch into, correct? It will be even more complete now. We’ve been anticipating that competitors would launch in that category, and two of our competitors are, in fact, at different stages of launching in the core plating category. There will be a certain amount of trial and a certain amount of adoption as those competitors launch in that category. We are seeing some effect from that, and that isn’t a new factor—it has simply been present in the market. I think our EVOS compares very, very favorably with competitors’ offerings, but over time, as surgeons try those, you’ll see some quarterly variations depending on who is trying and who has adopted, and so forth, correct? I feel very good about our positioning in that category. We do have our own drivers beyond EVOS. IM nails—we launched that, I believe in Q1, and you’ll have to remind me, John, but in the recent quarter or two, we launched our own IM nail offering.
My sales force enjoys reminding me that we hadn't launched a new product in that area for far too long. We now have a solid offering there that ought to help drive growth, and we highlighted it during the last quarter. The core trauma category is well positioned when it comes to our products, though competitor launches exist, especially in plating. Turning to extremities, we're a relatively small player at present, and for us the key point to flag here is shoulder with AETOS, correct? Again, in that area we remain a relatively small player, but at this point we have more or less the offering we need on the implant side, and importantly, we've got CORI enabled for planning and execution, and there's genuine differentiation within that: anatomic, reverse anatomic, glenoid and humeral planning and execution, which is a fairly distinctive feature, and in that setting a handheld robot is in fact differentiated relative to a fixed-arm robot for shoulder surgery. We're starting from a small base, and we're in the early stages of launch. It will be more relevant at the group level, I'd say, in '27 and '28. We're at that early stage, and we're seeing good traction not only with surgeons who are trying it, but with surgeons who have actually made it part of their routine practice.
It's in there — it's simply less significant for the group, considering the small base. I hope that provides a little texture and color regarding trauma and extremities. Regarding the mid-term guidance, look, as I mentioned, '26 was softer. Veronika, you worked through some of the numbers around 4% and then 6 to 7%. The reality is that we're 2 quarters into what is kind of a 3-year plan, correct? Naturally, we've reasoned through the numbers ourselves, and we've examined the fundamentals of what really drives that 6 to 7%. As I said before, once we get past the period today, what is restraining us this year, why did we in fact lower the guidance? First, it's our position in US knees and how that is affecting us now, with the gap in the portfolio, and the second is SANTYL, correct, with the prior authorization that we must deal with. On the skin subs side, we're at the upper end of the range, yet still inside the corridor we guided to. Taken together, that is not a great thing to have to navigate this year, because you have a bunch of headwinds and not many tailwinds.
Looking ahead to 2027, we anticipate the skin substitutes will get back to a normalized level, correct? We expect things to settle down on SANTYL, and at that point the portfolio will be whole in a manner that lets us compete effectively. Now, a ramp will begin in Q4 of this year, with cementless first, and then, and then beginning in the back half of next year with cemented LANDMARC, there's going to be a phasing, or a pacing, in how we grow more competitive in knees. When you combine all of that, we feel good about the growth drivers we have stacked up in Orthopaedics. I've mentioned knees and hips. It comes down to building execution capability in CORI. We are seeing contracting activity that links knees and hips together, and I believe we'll compete better there once we also have execution ability in CORI on the CORI XT platform. Then, as I've said, AETOS becomes more relevant during the '27, '28 period. Then in Sports, we've discussed the Big 4, and those are very attractive growth drivers that are sort of lined up inside that business unit. Then in Wound, beyond skin subs returning to normal, you have new product launches arriving in the traditional negative pressure category, where we have lost ground, and I've said before that that is one element of the 12-point plan that did not work so well, correct?
The growth rates themselves were strong, but if you looked at where RENASYS was placed, we lagged there. We've fixed that, and we get why it happened, but as we move into 2027 that becomes a driver of growth, along with what we've put into LEAF and next-gen PICO. When you add it all together, it gives us confidence that, ultimately, we're a company growing 6 to 7%, even with the difficulties we're working through in '26. Yep. We'll return to the room and then go back online.
Hi, can you hear me? This is Kane Shah from Deutsche. John, a quick question for you about the savings. Could you give us some reassurance that, I suppose, nothing that's been done over the past few years, or that still needs doing, is in some way harming growth further out? We often see these kinds of situations where cuts can go too close to the bone. Then just for Deepak, quickly returning to the US environment, you mentioned that some of it is slower growth. Your larger peers seem to push back against the sort of view that the market is weakening. One smaller peer suggested that we return to pre-COVID sort of growth rates. I'm just wondering whether you have any thoughts on that, with a view to obviously trying to launch.
I believe we can state categorically that we are not, in any sense, choking the business in order to produce growth. As a matter of fact, we are quite deliberately, very deliberately, putting investment into growing this business. We have been highly mindful of the way we both deliver cost and efficiency savings and actually put money into our growth. So much so that we laid it out separately in the bridge we provide to you, with genuinely excellent transparency. You can see the savings in that bridge, and you can see the roughly 33 million of investment we are making in growth. How does that look in practice? Put very simply, if you look at it purely in terms of headcount, and I am strongly in favor of reducing headcount wherever we can, but in fact across the last 12 months or so, we have in fact raised our headcount. We have in fact lowered our headcount, permanent headcount, in those areas where efficiency savings can be driven, for instance manufacturing and operations, we have in fact lowered our overall permanent headcount, and we have in fact raised our headcount almost solely in Sports and Wound, where we see quite specific opportunities for growing our business. Clearly, the Sports story is very clear, and Deepak has spoken about the four opportunities we have across CartiHeal and THESIS and REGENETEN, and et cetera, et cetera.
That is quite clear. Within Wound, we see opportunities across PICO, ACC, and skin subs. When you look at how our headcount has grown, every bit of that increase lands in Wound and Sports, and no less than 75% of it sits in the front line — meaning sales, medical education, and customer service. We are not adding to the back office. I can state plainly that we are recycling resource. We are pulling resource out of areas such as back office functions, where we are streamlining and removing cost, and putting it back into the front line to fuel that top-line growth. Now, a return on that investment will not show up within '26 — the roughly 33 million we are putting into that growth — but to Deepak's earlier comments about what gives us confidence in our ability to deliver, why do we believe we are a 6 to 7% growth company, well, because we are investing in that growth, and we are being very deliberate about it. We are spelling that out for you as well; it is not sort of baked into one lump in the bridge, we are very clearly separating the cost savings from the investment piece.
Just to add a couple of points on that. As we went through the 12-point plan journey, I'll tell you, given all the margin pressures we faced, it would have been easy for us to kind of hit the targets, especially in the years, the interim years, by cutting R&D. I can tell you that was a place we could have gone. Although we more or less got there at the end of the three-year period, you'll remember the periods in 2023, 2024, where there was tremendous margin pressure, and there's all questions whether we're going to get to kind of what we set out. We resisted the urge to do that, right? We maintained the level of investment in R&D in order to fuel the growth, and we're starting to see the benefits of that, and it will come even as we go through the next three years. It's a very conscious, life is a balancing act, but what we have actually held onto is to not cut the things that position this business for sustainable kind of growth over the longer term. John's talked about the trade-offs there in manufacturing and commercial and in particular in R&D as well. We've made sure that we have ring-fenced or protected the things that really drive the long-term growth of this business.
On your question about US procedure volume, my assumption is that it’s mostly in Orthopaedics—and believe it or not, pinning down what the market is actually doing is harder than you’d expect, right? The third-party data available here isn’t as robust as what you find in other areas. All of us are trying to work out, from a limited set of data points, what the market is really doing, right? I’ve been somewhat reluctant to weigh in on the market because we’ve faced performance challenges in the US, and historically I’ve been less front-footed about commenting on it. Our performance remains challenged now, but that isn’t necessarily all down to commercial execution. I have a bit more visibility into what’s happening in the market, so when I say there’s some market effect, that reflects what we can see. I couldn’t have said that even last year, let alone two years ago. Given that backdrop—the market isn’t as robust as third-party sources describe—I do think this is an exercise in triangulation. What do you look at? First, look at reimbursement, right? That information is public, and you can see what’s happening with how procedures—knees and hips—are reimbursed across various care settings, right?
You can see the effect that has had historically and what it is expected to do in 20 2027. That is a single data point. The other data point you have is the movement in site of care, correct? When you move from a hospital setting to an ASC, reimbursement levels come down, and there is an effect on ASPs as you make that transition, right? That is something very dynamic, but there is an impact there. On the other side, you have additional factors such as mix, correct? As you move from cemented to cementless, there is a mix benefit that works against the things I have mentioned. When you combine all these elements, determining what the market is doing in revenue terms and what it is doing in volume terms can be more difficult. Then there is the ACA impact you asked about earlier, which involves not only patients leaving the ACA rolls as they lose subsidies, but also what is actually happening to people in commercial programs who are not necessarily receiving those subsidies, yet their out-of-pocket fees have risen, their premiums have risen, and how that affects their desire, willingness, and ability to undergo elective procedures is yet another factor in this.
Considering everything you've laid out, what I observe—and what I observed during Q2—is a slowdown. My purpose here isn't to account for how we performed in the quarter. With any luck, that provides you some color regarding the market, the stance I've adopted, my reasons for adopting it, grounded in what I observe. Returning to the calls, yes.
Thanks. Caitlin Roberts <<inaudible>> from Canaccord has the next question over the phone lines. Your line is open now, so please proceed.
Thanks. Appreciate you taking the questions. Perhaps to begin with skin subs, what's your view on how this business recovers, given you mentioned the market is taking longer to adapt? Is there a chance this weakness carries into 2027? And are there efforts underway specifically aimed at helping the market adjust to these changes?
Okay, I believe your name is Caitlin — I didn't catch it earlier. Regarding skin substitutes, what's going on? To start, there's how skin substitutes are utilized across different settings. That includes the hospital setting, physician offices, HOPD settings — hospital outpatient departments — and Mobile, correct? In terms of impact, what we're discussing is greatest in the Mobile setting, then physician offices and hospital outpatient. For the most part, in-hospital use has not been affected by the reimbursement change. The second point concerns which products are being used, right? There are new entrants whose products lack substantial clinical data backing them, and then there are companies such as ours and a couple of others that have been in this market for a long time, with products that have stood the test of time and that have a great deal of clinical data supporting appropriate use in the clinic for those products. What's happening this year, now that the reimbursement change has been implemented, is that Mobile is where we anticipated the greatest impact, and that is what we're seeing. At Smith & Nephew, we've had the least exposure in the Mobile segment.
We've had exposure in the physician office and HOPD and office in the physician office, and we've detailed that before — you can look back at our earlier releases to see how we broke that out, right? Broadly speaking, that effect in Mobile office is unfolding the way we expected. In the physician office, the way they get reimbursed has shifted. There's the mechanics of how you bill for it — whether it's per application or per episode of care — and that has changed, right? As physician offices have adjusted to the new billing approaches, that's brought friction into the system, right? That piece has taken time. The reimbursement side has been slower as well, and roughly four MACs in the US have gone through or are currently covered under the WISeR model, which you've heard about, either from us or from other disclosures, where there's an AI-based algorithm for how claims are reimbursed, and there's been friction tied to that, right? What are we doing about it? We had always expected that the parts of our portfolio that we've always had uptake based on the clinical data and everything else, will get robust utilization, and we're seeing that.
Actually, our Oasis line is expanding tremendously, correct? That has been excellent. Going into 2027, all the administrative friction I'm referring to — whether it concerns the way claims are submitted or the way claims are handled, and how physicians adjust their care based on which products they use — we expect all of that to resolve in 2027 as the new calendar year, the new fiscal year in the United States, essentially rolls over. In that new environment, we anticipate being very well-positioned, since we have a product portfolio that is extremely relevant to that category, we have a price point that fits within the reimbursement level set by the government at $127 per square centimeter, and we have the clinical evidence for the products we intend to use. It's a great category, growing at a double digit rate when products are used appropriately, right, when it's relevant for a clinical setting, and we are very well-positioned within it. The real issue is navigating this year, which has been a challenge. Taking all of these factors into account, we provided a range of something like 20 to 40 million, right, we're navigating toward the upper end of that range, but we remain within that corridor that we had provided amid all of these dynamics.
As part of that, we had also asked for sequential improvement or normalization between the first half and the second half. From Q1 to Q2, sequential improvement has been observed, and we expect that trend to continue from first half to second half. Hopefully that unpacks the skin sub topic. Anything to add, John?
Let me add a little detail on the figures, since you'll recall that at the start of the year we guided that revenues would decline 15 to 20%, and the driver there was a price reduction of 20 to 25%, partly offset by a modest positive on volumes. That combination is what took us to the 20 to 40 range, and in fact we landed right in the middle of it, which is why we framed it as 20 to 40. What we've seen in practice is that first-half revenues were actually down roughly 20%, toward the upper end of that range. Broadly speaking, that's what we're forecasting now for the full year. We don't expect the price impact — the 20 to 25% we flagged before — to be quite so severe; the price effect will come in below that. By the same token, we're not really expecting volumes to be as flat to positive; we now expect a slight decline in volume. Volume has come in somewhat worse than we anticipated, price somewhat better than we anticipated, and the net-net is that we sit toward the upper end of that 20 to 40 million range.
That's not far off from our expectations. The key thing is what Deepak mentioned: on a sequential basis, Q2 came in stronger than Q1. The market is shifting, just somewhat more slowly than our initial forecast.
Okay, let's bring it back to the room. David, your hand's been raised for quite some time now.
Thanks, guys. David Adlington from JPMorgan. Sorry, John, just going back to tariffs — the net figure, I believe, came to 5 million in the first half, but I was just wondering what the gross number was. Was the full 50 million received during the first half, and how do you see that unfolding across the second half? Then I'm also curious how it was distributed among the three businesses.
It leans a bit toward Orthopaedics, and then somewhat more toward Sports, while Wound is the least affected — that's roughly how it plays out, though honestly it isn't hugely differentiated across all the businesses. Then basically, in the first half we saw a net benefit of around 5 million between tariffs and the refunds. In the second half, we expect a net benefit of roughly 1 million between the tariffs and the refunds. For the full year, it'll be plus or minus 4 million, 5 million, or something along those lines. Effectively, in both halves, on a year-on-year basis, the refund essentially offsets the tariff headwind.
That's great. Thanks a lot.
To be fully clear, we still anticipate a net tariff cost for the year, but whereas last year’s net tariff cost came to 15 million, for this year we expect that net tariff cost to be 10 million. That difference is a positive 5 million. Does that make sense?
I think we'll bring this to a close here, and just to recap. Our revenue results in the first half were, of course, under what we had expected, but we did turn in a strong profit performance, and by doing so, we showed the built-in resilience in our business that we've established. We stay confident about the steps we're taking to generate improved performance, more consistently as time goes on. I just want to take a moment to thank you for being with us today, we appreciate the engagement, the support, and your questions, and we very much look forward to returning to update you on our progress as we go forward. Thank you very much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Smith & Nephew plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Smith & Nephew plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.